Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma.
about
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerClinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Risk of cutaneous malignant melanoma in patients with celiac disease: a population-based studyAnticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report.Ipilimumab-induced colitis: experience from a tertiary referral center.Ipilimumab in the treatment of metastatic melanoma: management of adverse events.Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.Drug-induced liver injury: Do we know everything?Novel targets in the treatment of advanced melanoma: new first-line treatment options.Drug-induced liver injury: what was new in 2013?Anti-tumour effects of polysaccharides isolated from Artemisia annua L by inducing cell apoptosis and immunomodulatory anti-hepatoma effects of polysaccharides.Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Systematic review: colitis associated with anti-CTLA-4 therapy.Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM WorkshopHistopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study.Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy.A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer.
P2860
Q26795509-DE738CD2-ECED-40C5-B970-97D6D39C26D9Q33643902-911DEF16-92BC-4525-99C1-E74DAD9690AEQ33732329-ED0D8645-ADB7-480F-BB9C-241A94A15998Q33923131-879D1C06-2332-4A36-ACBE-3340B94E61E2Q35074088-0542774F-66F0-4B7E-8BCA-FA7790D931F0Q35713454-DA61F0D4-3FE9-43F1-AE6F-ED84B70855C6Q37019510-7ABB2AFB-A6A3-4FB6-88A2-FB69139D1454Q37601293-970332DE-3C80-4D2C-8D87-A8722102D44DQ37641262-12CA8F9C-907B-4B11-A604-6E49016F3126Q37748005-B5DC2295-A5F3-44AC-B01D-E344C7777AA7Q38095228-80B45757-9442-4A6B-BB4B-36B40696E996Q38205591-8A158A28-A4E5-43E8-B297-C6B395111574Q38311935-FB539435-D3C3-4AA9-B28B-CA981A8B5487Q38364937-B7073D5B-5A46-4458-998D-EB1DFA22B092Q38391533-41677071-ADAB-4D5A-9A94-41F8FAE88E45Q38529051-8A87D4E9-0A2B-40CA-B716-595CE41755DCQ38821875-C01A72E4-50AF-47A4-AE59-D6867A568417Q40340021-52AA1756-9AEF-4B2C-8744-BADB5B35E426Q46688417-73C9EA89-CDBF-4A03-B5B0-3F7DB8F951DEQ47120953-15EFE8E0-A233-4413-B1E7-F798764444CBQ47752171-0F557E3E-7EA6-4A67-A596-848E314BCF09Q50719439-B894A8E5-3F62-427F-BFC7-1C5F07030B50Q53656848-EEAD2FE8-099E-4124-B3CC-8FA4EFDB544EQ55263175-1AB49118-10AF-4C28-AF0A-4BC680056FAC
P2860
Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Characteristics and management ...... erapy for metastatic melanoma.
@ast
Characteristics and management ...... erapy for metastatic melanoma.
@en
type
label
Characteristics and management ...... erapy for metastatic melanoma.
@ast
Characteristics and management ...... erapy for metastatic melanoma.
@en
prefLabel
Characteristics and management ...... erapy for metastatic melanoma.
@ast
Characteristics and management ...... erapy for metastatic melanoma.
@en
P2860
P356
P1476
Characteristics and management ...... erapy for metastatic melanoma.
@en
P2093
Rita Holden
Stephanie Andrews
P2860
P304
P356
10.2147/CMAR.S31873
P407
P577
2012-09-12T00:00:00Z